Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes
Open Access
- 19 February 2025
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 27 (Supplement) , i1-i5
Abstract
Cardiovascular (CV) diseases (CVDs) remain a leading global health issue, causing about one-third of all deaths worldwide. Among modifiable CV risk factors (systolic blood pressure, non-HDL cholesterol, diabetes, body mass index, and smoking), diabetes is a leading one, accounting for established CVDs in 34.8% of diabetic patients, with an increasing prevalence of disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), like exenatide, liraglutide, albiglutide, dulaglutide, and semaglutide, initially developed for treatment of Type 2 diabetes, have shown CV benefits, and international guidelines recommend now GLP-1 RAs as preferred drugs for CV prevention in diabetic patients regardless of baseline HbA1c or metformin use. Among GLP-1 RAs, subcutaneous semaglutide has demonstrated cardio-metabolic risk factors reduction and efficacy in CV prevention. Development of oral semaglutide represents the evolution of the molecule. The PIONEER study programme confirmed the efficacy of oral semaglutide in reducing HbA1c, body weight, and cardio-metabolic risk factors as well as CV safety. Notably, independently by route of administration, semaglutide showed early CV benefits, suggesting mechanisms beyond glycaemic control or weight reduction. Semaglutide, combining potent cardio-metabolic effects with oral route, emerges as a pivotal treatment for high-risk Type 2 diabetes patients, offering comprehensive CV protection independent of HbA1c levels.Keywords
This publication has 15 references indexed in Scilit:
- 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetesEuropean Heart Journal, 2023
- Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2023
- Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of actionNature Reviews Cardiology, 2023
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023Diabetes Care, 2022
- Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trialsCardiovascular Diabetology, 2022
- A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetesReviews in Endocrine and Metabolic Disorders, 2022
- Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patientsCardiovascular Diabetology, 2021
- Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2021
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2019
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory PathwaysJACC: Basic To Translational Science, 2018